Palisade Bio Adds Global IBD Leaders Laurent Peyrin-Biroulet And David T. Rubin To Clinical Advisory Board As Company Prepares PALI-2108 For Development

Palisade Bio, Inc., a clinical-stage biopharmaceutical company developing next-generation, once-daily oral PDE4 inhibitor prodrugs targeted to the terminal ileum and colon, announced the addition of two leading global experts in inflammatory bowel disease (IBD) to its Clinical Advisory Board (CAB): Laurent Peyrin-Biroulet, MD, PhD, and David T. Rubin, MD.

According to JD Finley, Chief Executive Officer of Palisade Bio, both experts bring exceptional clinical and scientific leadership to the company’s advisory group. He noted that their deep experience in areas such as disease modification, fibrosis, treat-to-target approaches and clinical trial execution will play an important role as Palisade prepares PALI-2108 for clinical development. Their perspectives, combined with those of existing advisors, are expected to strengthen Palisade’s position in the emerging space of next-generation IBD therapies.

Dr. Laurent Peyrin-Biroulet is a Professor of Gastroenterology and one of the world’s most recognized authorities in Crohn’s disease, ulcerative colitis, intestinal fibrosis and treat-to-target strategies. He has authored more than 1,200 peer-reviewed publications and has held prominent leadership roles, including President of the European Crohn’s and Colitis Organization (ECCO) and Scientific Secretary of the International Organization for the Study of IBD (IOIBD). He also led the French IBD network GETAID from 2015 to 2023. 

His work has significantly shaped modern clinical endpoints, disease-modifying treatment strategies and regulatory pathways for new IBD therapies. Commenting on his appointment, Dr. Peyrin-Biroulet said he is encouraged by Palisade Bio’s focus on intestinal fibrosis and targeted PDE4 biology, an area with substantial unmet need especially in fibrostenotic Crohn’s disease and looks forward to supporting the advancement of PALI-2108.

Dr. David T. Rubin serves as the Joseph B. Kirsner Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition at the University of Chicago. He also chairs the International Organization for the Study of IBD (IOIBD) and directs the University of Chicago IBD Center. Dr. Rubin is internationally regarded for his expertise in ulcerative colitis, Crohn’s disease, clinical trial methodology and real-world evidence generation. He has contributed to the development and evaluation of multiple approved IBD therapies and previously chaired the Crohn’s & Colitis Foundation’s National Scientific Advisory Committee. 

Dr. Rubin stated that he is pleased to join Palisade’s Clinical Advisory Board at a pivotal time for the company and emphasized the importance of developing therapies that can alter disease progression in IBD. He expressed his enthusiasm for helping guide clinical strategy and ensuring high-quality trial design as PALI-2108 moves forward. This expanded Clinical Advisory Board is expected to provide Palisade Bio with critical insights as the company advances its pipeline of targeted, next-generation IBD therapies.